A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Study acronym: CLARITY-CRP
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 19 of 46 sites
  2. Site contacts updated at 15 of 46 sites
    • Eligibility criteria expanded, about 2 words
  3. Recruitment opened
    • Study sites: 47 to 46
    • Start date changed from estimate of Sep 2026 to Aug 27, 2026
    • Eligibility criteria expanded, about 28 words
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Heart Disease
8,814 trials monitored
See 428 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
and 3 more diseases
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.
Trial Details
NCT Number NCT07783802
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Related terms Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypertension, Obesity, Renal Insufficiency, Chronic
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov